Time point | Age group | Antigen | Signature of protection | Generalization capability | Accuracy |
CPS | |||||
Postimmunization | Adults | CSP/DMSO | F2, CXCL10, and KL | 87.50% | 87.50% |
Adults | PfRBC/uRBC | HSPA8, CALR, and CXCL16 | 70.83% | 70.83% | |
Adults | CSP/DMSO and PfRBC/uRBC | F2RL2, IL-3RA, and GNA11 | 81.25% | 93.75% | |
Preimmunization | Adults | CSP/DMSO | CSF2, NFkBIE, TNFRSF11B, and ITGA2 | 87.50% | 100% |
Adults | PfRBC/uRBC | PTK2, TGF-β3, and HSPA8 | 70.83% | 70.83% | |
Adults | CSP/DMSO and PfRBC/uRBC | CACNA2D2, CACNA1F, ITGB7, ARHGDIB, and KCNB1 | 77.08% | 89.58% | |
Pre- and postimmunization | Adults | CSP/DMSO | IL-7, ADRA2B, and F2RL2 | 89.58% | 93.75% |
RTS,S/AS01E | |||||
Postimmunization | Infants | CSP/DMSO | GNAT 3, SGK1, and TLR4 | 80% | 86.67% |
Infants | PfRBC/uRBC | TLR4, P85B, and SH2B2 | 82.69% | 88.46% | |
Children | CSP/DMSO | ERBB2, PRLR, and FAK2 | 80.49% | 92.68% | |
Children | PfRBC/uRBC | JAK2, NCAM1, VCAM1, CNTFR, and GNA11 | 80.65% | 100% | |
Infants and children | CSP/DMSO | ITB1, CASP6, and IL-18 | 79.29% | 83.57% | |
Infants and children | PfRBC/uRBC | M3K7, IL-3, FCG2A, and CBLC | 80% | 90% | |
Children | CSP/DMSO and PfRBC/uRBC | GNAT3, SGK1, and TLR4 | 81.94% | 84.72% | |
Preimmunization | Children | PfRBC/uRBC | TR10A, CCNE2, ADA2A, SRC, and IL-12B | 79.49% | 100% |
Children | CSP/DMSO | TLR4, WASL, and P85B | 81.13% | 86.79% | |
Children | CSP/DMSO and PfRBC/uRBC | TLR4, P85B, SH2B2, MAP2K7, and IKKB | 78.79% | 87.88% |